Orazol (zoledronic acid) / Merrion, Novo Nordisk - LARVOL DELTA

Treatment sequence key for optimal management of osteoporosis (Healio) - "'All osteoanabolic agents have been shown to reduce fractures and to increase bone mass and calculated hip bone strength. However, after they are used, both bone mass and bone strength rapidly deteriorate unless an antiresorptive agent is administered,' Lane told Endocrine Today...."

Media quote

Time to update "routine, repeated" use of bone metastasis drugs (Medscape) - "Hello. It's Mark Kris from Memorial Sloan Kettering, talking today about the treatment of bone metastases, particularly the use of zoledronic acid and denosumab in preventing problems brought on by bone metastases....I should also say that neither trial showed any clear improvement in pain, improvement in quality of life, or in harder endpoints of overall or disease-free survival."

Video

Large database reveals surprises in mCRPC management (Urology Times) - "Celestia Higano, MD...said 77% of patients received first-line therapy....“Only about 60% of the patients received any kind of so-called bone health agent, meaning either denosumab or zoledronic acid, which is rather odd since the [NCCN] guidelines clearly recommend that those be used unless there is an absolute contraindication,” Dr. Higano said."

Interview • Video